Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$502.42 USD
-1.47 (-0.29%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $506.86 +4.44 (0.88%) 4:22 PM ET
3-Hold of 5 3
A Value F Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$502.42 USD
-1.47 (-0.29%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $506.86 +4.44 (0.88%) 4:22 PM ET
3-Hold of 5 3
A Value F Growth A Momentum B VGM
Zacks News
Inari Medical (NARI) Q2 Earnings Top, Revenues Rise Y/Y
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
Cigna (CI) Q2 Earnings Beat on Strong U.S. Commercial Unit
by Zacks Equity Research
Cigna's (CI) Q2 results reflect solid premium rate hikes and a growing membership base across its U.S. Commercial and Medicare Advantage businesses.
Envista (NVST) Q2 Earnings Top Estimates, Margins Expands
by Zacks Equity Research
Consistent growth in the Specialty Products & Technologies segment and a return to growth in the Equipment & Consumables segment drive Envista's (NVST) Q2 revenues.
Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) second-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
STERIS (STE) Q1 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
Barring Life Sciences and Dental, rest of STERIS (STE) operating segments report organic revenue growth in fiscal Q1.
McKesson (MCK) Q1 Earnings Beat Estimates, U.S. Sales Strong
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2024 results benefit from growth in the United States. Divestment hurts the International segment.
Fresenius Medical (FMS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter revenues benefit from strong performance across all segments. Inflationary pressure continues to improve, benefiting operating income.
DENTSPLY SIRONA (XRAY) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q2 revenues are driven by a rise in demand across key markets, especially in China. Improved pricing and restructuring initiatives boost earnings.
NuVasive (NUVA) Q2 Earnings Meet Estimates, Margins Down
by Zacks Equity Research
NuVasive's (NUVA) second-quarter 2023 results reflect the robust performance of the U.S. Cervical business.
CVS Health (CVS) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Pharmacy drug mix, growth in specialty pharmacy, brand inflation and the acquisitions of Oak Street Health and Signify Health drive CVS Health's (CVS) Q2 revenues.
Penumbra (PEN) Q2 Earnings Top Estimates, Sales View Raised
by Zacks Equity Research
Penumbra's (PEN) U.S. thrombectomy records 50% year-over-year growth, while the international Vascular business sees relatively flat sales in the second quarter.
Exact Sciences (EXAS) Beats on Q2 Earnings, Ups '23 Sales View
by Zacks Equity Research
Strength in Screening revenues and Precision Oncology drive Exact Sciences (EXAS) Q2 performance.
AmerisourceBergen (ABC) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.
Revvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS View
by Zacks Equity Research
Revvity's (RVTY) second-quarter results reflect the impact of lower COVID-related sales. Both earnings and sales outpace their respective consensus estimate.
Omnicell (OMCL) Q2 Earnings and Revenues Top, '23 View Raised
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2023 performance reflects strength in advanced services and technical services as well as continued strong execution.
Tenet Healthcare (THC) Q2 Earnings Beat on Solid Hospital Unit
by Zacks Equity Research
Tenet Healthcare's (THC) Q2 results gain on improved adjusted admissions and higher pricing yield. Management expects adjusted EPS of $5.18-$6.03 for this year.
Hologic's (HOLX) Q3 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
Strength in Breast Health and GYN Surgical drives Hologic's (HOLX) Q3 performance.
IDEXX (IDXX) Q2 Earnings and Revenues Beat Estimates, View Up
by Zacks Equity Research
IDEXX (IDXX) delivers better-than-expected earnings and revenues in the second quarter of 2023, backed by CAG Diagnostics' recurring revenue growth.
Zimmer Biomet (ZBH) Q2 Earnings Match Estimates, View Raised
by Zacks Equity Research
Barring S.E.T., Zimmer Biomet (ZBH) records strong growth across each of its business segments in the second quarter.
Avantor (AVTR) Q2 Earnings Lag Estimates, FY23 View Revised
by Zacks Equity Research
Despite Avantor's (AVTR) strength in end markets, it reports an overall soft second-quarter performance.
Ensign Group (ENSG) Beats on Q2 Earnings, Raises '23 EPS View
by Zacks Equity Research
Ensign Group's (ENSG) second-quarter results benefit from improved occupancies, skilled and managed care revenue. Rising expenses acted as a partial offset.
Integer Holdings (ITGR) Q2 Earnings Top Estimates, FY23 View Up
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.
Centene (CNC) Q2 Earnings Beat Estimates on Membership Growth
by Zacks Equity Research
Centene's (CNC) Q2 results benefit from growing premium and service revenues coupled with improving membership.
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.
Integra's (IART) Q2 Earnings Top Estimates, 2023 View Cut
by Zacks Equity Research
In CSS, Integra (IART) registers strong growth owing to high single-digit growth in Advanced Energy and mid-single-digit growth in CSF management during Q2.